Trevi Therapeutics to Announce Q1 2024 Financial Results and Corporate Update on May 7, 2024
Trevi Therapeutics, Inc., a biopharmaceutical company listed on Nasdaq as TRVI, is advancing the investigational therapy Haduvio™ (oral nalbuphine ER) designed for treating chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). On May 1, 2024, the company announced that its senior management would conduct a conference call and live audio webcast on May 7, 2024, at 4:30 p.m. ET. This event will provide a comprehensive corporate update and discuss the financial results for the quarter ending March 31, 2024.
Interested parties can join the live conference call by dialing (888) 317 6003 within the United States or (412) 317 6061 for international callers. The live audio webcast will be accessible through the 'Investors & News' section of the company's website, and an archived replay will be available on the site for 30 days following the event.
Trevi Therapeutics specializes in the development of Haduvio™ (oral nalbuphine ER), which targets chronic cough in IPF and RCC, as well as prurigo nodularis. Haduvio operates as a dual ĸ-opioid receptor agonist and µ-opioid receptor antagonist, functioning both centrally in the brain and peripherally in the lungs. This dual action offers a potential synergistic effect to alleviate chronic cough.
Chronic cough significantly impacts patients' lives, causing declines in social, physical, and psychological well-being. In IPF patients, chronic cough can exacerbate the disease, leading to increased risks of progression, mortality, or the need for lung transplantation. Currently, no approved therapies exist for treating chronic cough in IPF, and available treatments provide limited relief. The condition of refractory chronic cough (RCC), affecting up to 10% of the adult population, represents another potential market for Haduvio, especially for those with moderate to severe symptoms. Similarly, no approved therapies for RCC are available in the United States.
Parenteral nalbuphine is not regulated by the U.S. Drug Enforcement Agency, and Trevi plans to propose Haduvio as the trade name for the oral nalbuphine ER formulation. It is important to note that the safety and efficacy of Haduvio have not yet been evaluated by any regulatory authority.
Trevi Therapeutics continues to focus on advancing its investigational therapies to address significant unmet medical needs, particularly in the areas of chronic cough and prurigo nodularis. The company aims to provide innovative solutions that can improve the quality of life for patients suffering from these debilitating conditions.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
